Kineta Acquires Novel Drug Candidates From Airmid For Potential Treatment Of Multiple Sclerosis, Type 1 Diabetes And Other Autoimmune Diseases
Links shared publicly online about this topic.
- 1,915total visits
Kineta Acquires Novel Drug Candidates From Airmid For Potential Treatment Of Multiple Sclerosis, Type 1 Diabetes And Other Autoimmune Diseases
Kineta, Inc. of Seattle and Airmid Incorporated of Redwood City, CA jointly announce an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel ther
View full resource at medicalnewstoday.com
Tags: Diabetes, Type 1 Diabetes, Multiple Sclerosis, Autoimmune Disease, Disease and Condition, Drug
Most Recently Shared on July 7, 2009 at 5:11 pm By:
MedNewsToday: Kineta Acquires Novel Drug Candidates From Airmid For Potential Treatment Of Multiple.. http://tinyurl.com/l89jx8
Advertisement
